News
Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback